Skip to nav Skip to content

Clinical Trial Search

25 Clinical Trials Found

Clinical Trial 23691

A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Disease Site: Larynx, Lip, Oral Cavity and Pharynx
PI: Chung, Christine

Clinical Trial 21657

Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Disease Site: Head & Neck, Larynx, Lip, Oral Cavity and Pharynx, Mouth, lip
PI: Chung, Christine

Clinical Trial 21421

A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigators Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma
Disease Site: Lip, Oral Cavity and Pharynx
PI: Caudell, Jimmy

Clinical Trial 22716

Phase III Randomized Trial of Immunotherapy with or without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma
Disease Site: Larynx, Lip, Oral Cavity and Pharynx
PI: Caudell, Jimmy

Clinical Trial 21641

First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGF_ Fusion Protein BCA101 Alone and in Combination with Pembrolizumab in Patients With EGFR-Driven Advanced Solid Tumors
Disease Site: Colon, Colorectal, Head & Neck, Larynx, Lip, Oral Cavity and Pharynx, Mouth, lip, Rectum
PI: Chung, Christine

Clinical Trial 17425

Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Disease Site: Larynx, Lip, Oral Cavity and Pharynx, Head & Neck, Mouth, lip
PI: Caudell, Jimmy

Clinical Trial 22485

Disease Site: Lip, Oral Cavity and Pharynx
PI: Chung, Christine

Clinical Trial 23115

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)
Disease Site: Larynx, Lip, Oral Cavity and Pharynx
PI: Chung, Christine

Clinical Trial 23480

Disease Site: Any Site, Breast, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Urinary Bladder
PI: Kim, Richard

Clinical Trial 23179

Disease Site: Breast, Lip, Oral Cavity and Pharynx, Lung, Urinary Bladder
PI: Vidrine, Damon

Clinical Trial 23803

Disease Site: Lip, Oral Cavity and Pharynx
PI: Vinci, Christine

Clinical Trial 17716

A Biomarker-related Approach to Screening for HPV-related Oropharyngeal Cancer
Disease Site: Larynx, Throat, Lip, Oral Cavity and Pharynx
PI: Giuliano, Anna